OOIR: Observatory of International Research

Papers

(The H4-Index of European Journal of Medicinal Chemistry is 59. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)

Article	Citations
Discovery of Sortase A covalent inhibitors with benzofuranene cyanide structures as potential antibacterial agents against Staphylococcus aureus	385
Editorial Board	308
Graphical abstract TOC	163
Editorial Board	159
Photosensitizer associated with efflux pump inhibitors as a strategy for photodynamic therapy against bacterial resistance	138
Design, synthesis and biological evaluation of galantamine analogues for cognitive improvement in Alzheimer's disease	134
Identification of a selective pyruvate dehydrogenase kinase 1 (PDHK1) chemical probe by virtual screening	131
Glycoconjugates of adefovir and tenofovir as asialoglycoprotein-mediated Anti-HBV prodrugs with enhanced liver targeting	124
Discovery of new and highly effective quadruple FFA1 and PPARα/γ/δ agonists as potential anti-fatty liver agents	120
Design and preclinical evaluation of 99mTc-Labeled dimer FAPI-46 derivatives as potential tumor radiotracers	119
Structural optimization and characterization of highly potent and selective STAT3 inhibitors for the treatment of triple negative breast cancer	116
Sialyl Lewis X (sLex):Biological functions, synthetic methods and therapeutic implications	116
Design, synthesis and biological evaluation of dual CDK9/PARP inhibitors for the treatment of cancer	108
Application of deuterium in research and development of drugs	106
[18F]R91150: Improved radiosynthesis and in vivo evaluation as imaging probe for 5-HT2A receptors	102
Correction of aberrant splicing of ELP1 pre-mRNA by kinetin derivatives – A structure activity relationship study	102
Discovery of novel fluorine-containing parthenolide analogues as potential antitumor agents	95
Research progress in bifunctional small molecules for cancer immunotherapy	94
Synthetic approaches and therapeutic applications of FDA-approved antibacterial agents: A comprehensive review from 2003 to 2023	91
Structure-based discovery of novel diarylpyrimidines as potent and selective Non-Nucleoside reverse transcriptase inhibitors: From CH(CN)-Biphenyl-Diarylpyrimidines to C NNH2-Biphenyl-Diarylpyrimidine	89
Design, synthesis, and biological evaluation of novel quinoline carboxylic acid based styryl/alkyne hybrid molecule as a potent anti-adipogenic and antidyslipidemic agent via activation of Wnt/β-caten	86
Insights into NEK2 inhibitors as antitumor agents: From mechanisms to potential therapeutics	86
Discovery of highly potent dual GSPT1/BRD4 degraders with anti-AML activity	84
Discovery of novel thiazole-pleuromutilin derivatives with potent antibacterial activity	83
The assembled decoders to prepare for “bioactive X″ against progressive deterioration of liver disease: From NAFLD to HCC	83

Discovery of novel dual tubulin and MMPs inhibitors for the treatment of lung cancer and overcoming drug resistance	81
Synthesis and evaluation of piceatannol derivatives as novel arginase inhibitors with radical scavenging activity and their potential for collagen reduction in dermal fibroblasts	81
A review of kappa opioid receptor antagonists and their clinical trial landscape	81
Insights into tumor-derived exosome inhibition in cancer therapy	80
Pyrimidine-based dual-target inhibitors targeting epidermal growth factor receptor for overcoming drug resistance in cancer therapy(2006-present)	80
Recent advances in small molecule design strategies against hepatic fibrosis	79
Synthesis and biological assessment of BUB1B inhibitors for the treatment of clear cell renal cell carcinoma	79
Optimization of potent, broad-spectrum, and specific anti-influenza compounds targeting RNA polymerase PA-PB1 heterodimerization	77
Novel α-mangostin derivatives as promising antiviral agents: Isolation, synthesis, and evaluation against chikungunya virus	76
Recent research and development of inhibitors targeting sentrin-specific protease 1 for the treatment of cancers	75
Graphical abstract TOC	75
A novel series of teriflunomide derivatives as orally active inhibitors of human dihydroorotate dehydrogenase for the treatment of colorectal carcinoma	74
The polyamino-isoprenyl potentiator NV716 revives disused antibiotics against Gram-negative bacteria in broth, infected monocytes, or biofilms, by disturbing the barrier effect of their outer membrane	73
Discovery of novel Thieno[2,3-d]imidazole derivatives as agonists of human STING for antitumor immunotherapy using systemic administration	72
Corrigendum to “Design, synthesis, and evaluation of novel pleuromutilin aryl acrylate derivatives as promising broad-spectrum antibiotics especially for combatting multi-drug resistant gram-negative	72
PRMT7 in cancer: Structure, effects, and therapeutic potentials	71
Design, synthesis and biological evaluation of novel β-carbolines as antitumor agents via targeting autophagy in colorectal cancer	71
Discovery of SET domain-binding primary alkylamine-tethered degraders for the simultaneous degradation of NSD2-long and RE-IIBP isoforms	70
Clinically approved representative small-molecule drugs for cardiopathy therapy	70
Corrigendum to “Discovery of indazole inhibitors for heat shock protein 90 as anti-cancer agents” [Eur. J. Med. Chem. (2024) 116620]	69
Praeruptorin A screened by a ferrous ion probe inhibited DMT1 and ferroptosis to attenuate Doxorubicin-induced cardiomyopathy	68
Tyrosine kinase 2 inhibitors: Synthesis and applications in the treatment of autoimmune diseases	66
Circumventing Imatinib resistance in CML: Novel Telmisartan-based cell death modulators with improved activity and stability	65
Advancing mitochondrial therapeutics: Synthesis and pharmacological evaluation of pyrazole-based inhibitors targeting the mitochondrial pyruvate carrier	65
Quinoline heterocyclic containing plant and marine candidates against drug-resistant Mycobacterium tuberculosis: A systematic drug-ability investigation	64
Hypoxia-selective prodrug restrains tumor cells through triggering mitophagy and inducing apoptosis	64
Dual 5-HT6/SERT ligands for mitigating neuropsychiatric symptoms of dementia exerting neuroprotection against amyloid-β toxicity, memory preservation, and antidepressant-like properties	64
Regioselective pyrrolizidine bis-spirooxindoles as efficient anti-amyloidogenic agents	63
Synthesis, structure-activity relationships and molecular docking studies of phenyldiazenyl sulfonamides as aromatase inhibitors	62
Targeting phosphatases: From molecule design to clinical trials	62
EGCG-like non-competitive inhibitor of DYRK1A rescues cognitive defect in a down syndrome model	61
PROTAC unleashed: Unveiling the synthetic approaches and potential therapeutic applications	61
Synthesis and antibacterial medicinal evaluation of carbothioamido hydrazonyl thiazolylquinolone with multitargeting antimicrobial potential to combat increasingly global resistance	61
Discovery of a novel Xanthone derivative P24 for anti-AD via targeting sTGFBR3	60
Identification, in-vitro anti-plasmodial assessment and docking studies of series of tetrahydrobenzothieno[2,3-d]pyrimidine-acetamide molecular hybrids as potential antimalarial agents	59